Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Celgene, Agios beat a short path to an FDA decision on AML drug
Celgene, Agios beat a short path to an FDA decision on AML drug
Celgene, Agios beat a short path to an FDA decision on AML drug
Submitted by
admin
on March 1, 2017 - 8:53pm
Source:
Endpoints
News Tags:
Celgene
Agios
FDA
AML
enasidenib
acute myeloid leukemia
Headline:
Celgene, Agios beat a short path to an FDA decision on AML drug
Do Not Allow Advertisers to Use My Personal information
